Tumor and Circulating Markers as Links Between Obesity and Lethal Prostate Cance
肿瘤和循环标志物作为肥胖与致命性前列腺癌之间的联系
基本信息
- 批准号:8764821
- 负责人:
- 金额:$ 39.42万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2002
- 资助国家:美国
- 起止时间:2002-09-19 至
- 项目状态:未结题
- 来源:
- 关键词:AddressAspirinAtrophicBiochemicalBiological MarkersBlood CirculationBlood specimenBody Weight decreasedCancer PatientCancer PrognosisChronicDNA Sequence RearrangementDana-Farber Cancer InstituteDataDevelopmentDiagnosisDiseaseETV1 geneEpidemicEtiologyEvolutionGenesGenomeGenomicsGoalsGrowthHigh PrevalenceHyperplasiaInflammationInflammatoryInsulinLaboratory StudyLeadLesionLightLinkMalignant NeoplasmsMalignant neoplasm of prostateMediatingMediationMediator of activation proteinMessenger RNAMetabolicMetabolismMetastatic toMetforminMolecular ProfilingMutationNuclearObesityOverweightParticipantPathway interactionsPatientsPopulation SciencesPreventionPrevention strategyProstateProstaticProstatic NeoplasmsPublic HealthRiskRisk FactorsRoleSecondary PreventionSeedsSignal TransductionSoilSubgroupTMPRSS2 geneTestingTimeTissuesTranslationsTumor MarkersWorkadiponectinanthrax lethal factorbasebiobankcancer recurrencedesignhigh riskinflammatory markerinsightmRNA Expressionmenmodifiable riskmortalityneoplastic cellnovelnovel strategiesoutcome forecastpopulation basedrandomized trialsuccesstumortumor metabolismtumor progression
项目摘要
Obesity is a public health problem globally, and two-thirds of US men are overweight or obese. For prostate cancer patients, the obesity epidemic is of concern since men who are overweight before or at the time of diagnosis are at increased risk of biochemical recurrence and cancer-specific mortality. There are several outstanding questions underlying the association between obesity and lethal prostate cancer whose answers are needed to shed light on the translational potential among prostate cancer patients.
Our study aims to elucidate mechanisms underlying the link between obesity and lethal prostate cancer and identify patient subgroups more susceptible to the obesity milieu. We hypothesize that obesity may act through local tumor effects which are We hypothesize that obesity may act
through local tumor effects which are "the seed" to increase a prostate cancer's lethal potential as well as via
systemic effects that fuel "the soil" for metastatic growrth. We focus on metabolism and inflammation
pathways - two domains with established links to obesity—and investigate biomarkers iri locally in prostate
tissue as well as in circulation. Moreover, we employ a discovery-based aim in tumors to identify novel
pathways enriched in the tumors of prostate cancer patients who are overweight and develop lethal cancer,
and endeavor that may unveil new opportunities for secondary prevention. Our population-based study of
obesity and lethal prostate cancer is nested among men with incident prostate cancer who were participants
within the DF/HCG SPORE in Prostate Gancer biorepository for whom prostate tissue and blood specimens
are available, and uniquely focuses on lethal cancer as the primary endpoint.
Obesity represents a means to discover drivers of lethal prostate cancer, as well as being a modifiable risk
factor in secondary prevention. Weight loss is challenging, and thus identifying specific pathways in tumors
and in circulation most strongly underlying the obesity-lethal prostate cancer link is critical to inform on
optimal prevention strategies. The translational goals ofthe project are the identification of patients at high
risk of the consequences of obesity in order to inform the design of randomized trials and augment the
success of secondary prevention strategies. The work will lead to a detailed understanding of the effect of
prostatic and systemic drivers of obesity on lethal prostate cancer, an endeavor that will strengthen causality
of the association.
肥胖是一个全球性的公共卫生问题,三分之二的美国男性超重或肥胖。对于前列腺癌患者,肥胖流行是令人担忧的,因为在诊断之前或诊断时超重的男性的生化复发和癌症特异性死亡率的风险增加。肥胖和致命性前列腺癌之间的关联有几个悬而未决的问题,需要这些问题的答案来阐明前列腺癌患者中的转化潜力。
我们的研究旨在阐明肥胖和致死性前列腺癌之间联系的潜在机制,并确定更易受肥胖环境影响的患者亚组。我们假设肥胖可能通过局部肿瘤效应起作用,
通过局部肿瘤效应,这是增加前列腺癌致命潜力的“种子”,以及通过
系统性影响,为转移性生长提供“土壤”。我们专注于新陈代谢和炎症
途径--两个与肥胖有联系的领域--并研究前列腺局部的生物标志物IRI
组织和循环中。此外,我们在肿瘤中采用基于发现的目的来识别新的
在超重并发展成致命癌症的前列腺癌患者的肿瘤中富集的途径,
并奋进为二级预防提供新的机会。我们的基于人群的研究
肥胖和致命的前列腺癌嵌套在参与者中患有前列腺癌的男性中
在前列腺癌生物储存库中的DF/HCG孢子内,
可用,并且独特地专注于致命癌症作为主要终点。
肥胖是发现致命前列腺癌驱动因素的一种手段,也是一种可改变的风险
二级预防的因素。减肥具有挑战性,因此要确定肿瘤中的特定途径
在循环中,肥胖与致命的前列腺癌之间的联系是至关重要的,
最佳预防策略。该项目的翻译目标是识别高血压患者,
肥胖后果的风险,以便为随机试验的设计提供信息,
二级预防战略的成功。这项工作将导致详细了解的影响,
前列腺和全身肥胖的驱动因素对致命的前列腺癌,一项奋进,将加强因果关系
协会的。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Lorelei Mucci其他文献
Lorelei Mucci的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Lorelei Mucci', 18)}}的其他基金
Cancer Epidemiology Cohort in Male Health Professionals
男性健康专业人员中的癌症流行病学队列
- 批准号:
10273315 - 财政年份:2021
- 资助金额:
$ 39.42万 - 项目类别:
Circadian Disruption and Risk of Prostate Cancer in a Multiethnic Cohort
多种族人群的昼夜节律紊乱和前列腺癌风险
- 批准号:
9017298 - 财政年份:2016
- 资助金额:
$ 39.42万 - 项目类别:
Cancer Epidemiology Cohort in Male Health Professionals
男性健康专业人员中的癌症流行病学队列
- 批准号:
10387375 - 财政年份:2012
- 资助金额:
$ 39.42万 - 项目类别:
Cancer Epidemiology Cohort in Male Health Professionals
男性健康专业人员中的癌症流行病学队列
- 批准号:
9750056 - 财政年份:2012
- 资助金额:
$ 39.42万 - 项目类别:
Cancer Epidemiology Cohort in Male Health Professionals
男性健康专业人员中的癌症流行病学队列
- 批准号:
10224870 - 财政年份:2012
- 资助金额:
$ 39.42万 - 项目类别:
Cancer Epidemiology Cohort in Male Health Professionals
男性健康专业人员中的癌症流行病学队列
- 批准号:
10625288 - 财政年份:2012
- 资助金额:
$ 39.42万 - 项目类别:
Cancer Epidemiology Cohort in Male Health Professionals
男性健康专业人员中的癌症流行病学队列
- 批准号:
9242751 - 财政年份:2012
- 资助金额:
$ 39.42万 - 项目类别:
相似国自然基金
Aspirin调控AKT/Foxo3a/BIM通路延缓吡咯替尼耐药作用机制研究
- 批准号:n/a
- 批准年份:2022
- 资助金额:0.0 万元
- 项目类别:省市级项目
Aspirin与自噬通路及核转录因子FoxG1在听觉系统退行性变中的协同调控机制研究
- 批准号:81800915
- 批准年份:2018
- 资助金额:21.0 万元
- 项目类别:青年科学基金项目
Aspirin联合牙周膜干细胞再生全脱位牙牙周组织机制研究
- 批准号:81760190
- 批准年份:2017
- 资助金额:32.0 万元
- 项目类别:地区科学基金项目
可注射温敏型水凝胶缓释Aspirin碳点和EPO促牙周组织再生的研究
- 批准号:81600879
- 批准年份:2016
- 资助金额:17.0 万元
- 项目类别:青年科学基金项目
Aspirin协同IFN-α抑制肝癌转移复发的作用及机制研究
- 批准号:30972889
- 批准年份:2009
- 资助金额:31.0 万元
- 项目类别:面上项目
胃癌microRNA特异表达与靶基因调控及Aspirin的作用
- 批准号:30873099
- 批准年份:2008
- 资助金额:35.0 万元
- 项目类别:面上项目
相似海外基金
Postpartum low-dose aspirin to augment vascular recovery following a hypertensive disorder of pregnancy
产后小剂量阿司匹林可促进妊娠高血压疾病后的血管恢复
- 批准号:
10644089 - 财政年份:2023
- 资助金额:
$ 39.42万 - 项目类别:
Aspirin, Lp(a) and Primary Prevention of Cardiovascular Events
阿司匹林、Lp(a) 和心血管事件的一级预防
- 批准号:
10720757 - 财政年份:2023
- 资助金额:
$ 39.42万 - 项目类别:
Early Double Low-Dose Aspirin to Reduce Preeclampsia and Miscarriage: a Global Approach RCT
早期双倍低剂量阿司匹林减少先兆子痫和流产:全球方法随机对照试验
- 批准号:
10711793 - 财政年份:2023
- 资助金额:
$ 39.42万 - 项目类别:
Aspirin for Primary Prevention of Cardiovascular Disease in Patients with Elevated Lipoprotein(a)
阿司匹林用于脂蛋白升高患者心血管疾病的一级预防(a)
- 批准号:
10739016 - 财政年份:2023
- 资助金额:
$ 39.42万 - 项目类别:
The PARTUM (Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity) Trial
PARTUM(产后阿司匹林减少血栓栓塞过度发病率)试验
- 批准号:
498295 - 财政年份:2023
- 资助金额:
$ 39.42万 - 项目类别:
Operating Grants
Health Outcomes of Discontinuing Aspirin in Older Adults with Alzheimer's Disease and Related Dementias
患有阿尔茨海默病和相关痴呆症的老年人停用阿司匹林的健康结果
- 批准号:
10662129 - 财政年份:2023
- 资助金额:
$ 39.42万 - 项目类别:
A study on the use of aspirin mini tablets for children with Kawasaki disease for the practical application of mini tablets
阿司匹林迷你片在川崎病患儿中的应用研究
- 批准号:
23K16462 - 财政年份:2023
- 资助金额:
$ 39.42万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Is Aspirin a Cost-Effective Thromboprophylaxis Alternative for Orthopaedic Trauma Patients?
阿司匹林是骨科创伤患者经济有效的血栓预防替代方案吗?
- 批准号:
10784156 - 财政年份:2023
- 资助金额:
$ 39.42万 - 项目类别:
Aspirin and severe maternal morbidity and mortality and adverse pregnancy outcomes
阿司匹林与严重孕产妇发病率和死亡率以及不良妊娠结局
- 批准号:
469014 - 财政年份:2022
- 资助金额:
$ 39.42万 - 项目类别:
Operating Grants
Effects of inflammaging on intestinal epithelial cells and aspirin chemoprevention.
炎症对肠上皮细胞的影响和阿司匹林化学预防。
- 批准号:
10152090 - 财政年份:2021
- 资助金额:
$ 39.42万 - 项目类别: